Navigation Links
NeuroPhage Awarded Second Grant from Michael J. Fox Foundation for Parkinson's Disease Research
Date:12/19/2013

CAMBRIDGE, Mass., Dec. 19, 2013 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc. today announced that it has been awarded an $822,000 grant by The Michael J. Fox Foundation for Parkinson's Research (MJFF) for its second-generation drug candidate, NPT088, based on NeuroPhage's GAIM (general amyloid interaction motif) platform, which simultaneously targets multiple misfolded proteins central to many neurodegenerative diseases. In particular, the MJFF grant will be applied to research the effect of NPT088 on alpha-synuclein deposits in the brain, a pathological hallmark of Parkinson's disease (PD). This is NeuroPhage's second grant from MJFF applied to the GAIM platform.

"NeuroPhage is honored to receive its second grant from the MJFF, which supports our GAIM platform as a unique approach to the treatment of PD and other neurodegenerative diseases characterized by deposits of misfolded proteins. This award will allow us to make continued progress on our program in PD with our second-generation candidate, NPT088, continuing to build on our strong preclinical data," said Kimberley S. Gannon, PhD, Senior Vice President of Preclinical R&D at NeuroPhage.

The proceeds of the new MJFF grant will be used to test the effect of NPT088 on alpha-synuclein accumulation in the brain in a preclinical model of PD. The preclinical study will be conducted in collaboration with Dr. Eliezer Masliah at the University of California, San Diego. NeuroPhage previously demonstrated that a single treatment of NPT001, a first-generation GAIM molecule, produced significant reductions in neuropathology along with improved motor performance in preclinical PD models.

"We are pleased with the progress that NeuroPhage has made since our original collaboration began in June 2011 under a Therapeutics Development Initiative Award," said Kuldip Dave, PhD, Senior Associate Director of Research Programs at MJFF. "NeuroPhage's unique approach has been successful in reducing alpha-synuclein levels in the brain and improving motor function preclinically. Alpha-synuclein is a high priority target for our Foundation, and this is a promising approach for the treatment of PD."

NPT088 is in development for the treatment of conditions characterized by multiple misfolded proteins, with initial focus on PD and Alzheimer's disease (AD). Multiple misfolded proteins are often present in such diseases and can increase disease severity and accelerate disease progression.

About Parkinson's Disease

Parkinson's disease is a chronic, progressive disorder of the central nervous system and results from the loss of cells in an area of the brain called the substantia nigra. These cells produce dopamine, a chemical messenger responsible for transmitting signals within the brain. Loss of dopamine causes critical nerve cells in the brain, or neurons, to fire out of control, leaving patients unable to direct or control their movement in a normal manner. The symptoms of Parkinson's may include tremors, difficulty maintaining balance and gait, rigidity or stiffness of the limbs and trunk, and general slowness of movement (also called bradykinesia). Patients may also eventually have difficulty walking, talking, or completing other simple tasks. Symptoms often appear gradually yet with increasing severity, and the progression of the disease may vary widely from patient to patient. There is no cure for Parkinson's disease. Drugs have been developed that can help patients manage many of the symptoms; however they do not prevent disease progression.

About The Michael J. Fox Foundation for Parkinson's Research

As the world's largest nonprofit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers.  In addition to funding more than $375 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world.

For more information, visit us on Facebook, Twitter, Web and LinkedIn.

About NeuroPhage

NeuroPhage Pharmaceuticals has fusion-protein drug candidates in development for neurodegenerative diseases, many of which cause progressive mental deterioration and dementia.  NeuroPhage's technology is based on a General Amyloid Interaction Motif (GAIM) that simultaneously targets multiple misfolded proteins or amyloids central to many neurodegenerative diseases such as Alzheimer's and Parkinson's diseases. In addition to targeting multiple misfolded pathological proteins, this unique disease-modifying approach recognizes early amyloid assemblies and existing protein aggregates to maximize potential therapeutic effect. NeuroPhage is initially developing candidates to treat Alzheimer's and Parkinson's disease, where a number of different misfolded proteins are present and their interactions can exacerbate disease progression. www.neurophage.com


'/>"/>
SOURCE NeuroPhage Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. NeuroPhage Receives Michael J. Fox Foundation Funding for Parkinsons Disease Research
2. NeuroPhage Extends Series B to $21.4M
3. K computer research results awarded ACM Gordon Bell Prize
4. BioPower Systems Awarded $5 Million from Victorian Government
5. Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager
6. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
7. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
8. Chinese Scientists Zhen-Yi Wang and Zhu Chen Awarded 7th Annual Szent-Gyorgyi Prize for Progress in Cancer Research
9. EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
10. Sloan Research Fellowships Awarded to 126 Young Scholars
11. Telome Health Co-founder and Nobel Laureate Elizabeth Blackburn Awarded Innovator of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... program for the development of future natural products for crop ... and development center in Israel and ... Stockton has a variety of products adapted to ... in more than 35 counties worldwide. ... product Timorex Gold ® is used to control a ...
(Date:2/6/2016)... ... February 06, 2016 , ... The Center for Excellence in Education ... high school teachers on Wednesday February 10, 2016. This Bite of Science session, ... of Conservation, located at 1500 Remount Road in Front Royal, VA from 5:00 p.m. ...
(Date:2/5/2016)... N.C. , Feb. 5, 2016  In the ... role for a host of launch activities including the ... of this launch activity is especially high in the ... Best Practices and the Role of Medical ... help companies focused on oncology therapies find better ways ...
(Date:2/5/2016)... 5, 2016 Australian-US drug discovery and development company, ... appointment of a new Chairman, Mr John O,Connor , ... immediately. James Garner , has also been ... former Acting CEO, Mr Iain Ross , will resume ... --> James Garner , has also been formally appointed ...
Breaking Biology Technology:
(Date:2/3/2016)... 2016 --> ... "Automated Fingerprint Identification System Market by Component (Hardware and ... & Finance, Government, Healthcare, and Transportation) and Geography - ... is expected to be worth USD 8.49 Billion by ... and 2020. The transformation and technology evolution from the ...
(Date:2/2/2016)... This BCC Research report provides a ... the recent advances in high throughput ‘omic platforms ... forward. Includes forecast through 2019. Use ... opportunities that exist in the bioinformatic market. Analyze ... well as IT and bioinformatics service providers. Analyze ...
(Date:2/2/2016)... MOUNTAIN VIEW, Calif. , Feb. 2, 2016 ... diabetic retinopathy market, Frost & Sullivan recognizes US-based ... North America Frost & Sullivan Award for New ... technology provider in North America ... standard in the rapidly growing diabetic retinopathy market. ...
Breaking Biology News(10 mins):